ASACOL an effective treatment for Ulcerative colitis, Proctosis and Proctosigmoiditis http://goo.gl/McmYWg. By: … Continue reading →

Treatment Of Ulcerative Colitis With Asacol http://goo.gl/McmYWg. By: … Continue reading →

Use Asacol to Get Rid Of Ulcerative Colitis http://goo.gl/McmYWg. By: … Continue reading →

Treat ulcerative colitis with Asacol http://goo.gl/McmYWg. By: … Continue reading →

- 18 abstract presentations including vedolizumab safety and efficacy data ZURICH, Feb. 20, 2015 /PRNewswire/ --Takeda Pharmaceuticals International GmbH ("Takeda") today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Findings from the Phase 3 pivotal GEMINI 1 (ulcerative colitis) and GEMINI 2 (Crohn's disease) studies, as well as interim data from the ongoing, open-label extension study GEMINI LTS (long-term safety) were presented as oral digital presentations and poster presentations during the 10th Congress of European Crohn's and Colitis Organisation (ECCO) in Barcelona, Spain. A total of 18 Takeda-sponsored abstracts were accepted for presentation at the meeting. "As ulcerative colitis and Crohn's disease are so complex to treat, ongoing scientific study and exchange are important to further understand the clinical benefits of vedolizumab," said Prof. Dr. Severine Vermeire, University Hospitals Leuven, Belgium. "These findings signify its promise as an important treatment option for patients." The GEMINI 1 and 2 studies are two randomized double-blind, placebo-controlled induction and maintenance studies examining the efficacy and safety of vedolizumab for induction and maintenance in adult patients with moderately to severely active UC … Continue reading →